Although the effects of YFAK and YEAK on plasma CCL22 and CXCL13 during induction of EAE and its therapy was not measured in these experiments, the analysis of serum CCL22 during administration of YFAK to patients with secondary progressive multiple sclerosis in a Phase Ib clinical trial was carried out and the appropriate elevation was observed [9]. This evidence concerns the gene CXCL13 and secondary progressive multiple sclerosis.